Dr. Reddy's Enters into a Licensing Agreement with Gilead for Remdesivir

Remdesivir, an investigational antiviral therapy developed by Gilead, received...
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization by the FDA to treat Covid-19. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this drug.

Dr. Reddy's Laboratories has entered into a non-exclusive licensing agreement with Gilead Sciences. The agreement will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat Covid-19. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this drug. The Hyderabad, India-based integrated pharmaceutical company said it would need to do the manufacturing scale-up and obtain regulatory approval for marketing of this drug in respective countries.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.